ICP 488
Alternative Names: ICP-488Latest Information Update: 22 May 2024
At a glance
- Originator InnoCare Pharma
- Class Anti-inflammatories; Antipsoriatics; Heterocyclic compounds; Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Plaque psoriasis
- Preclinical Inflammatory bowel diseases; Systemic lupus erythematosus
Most Recent Events
- 16 May 2024 Beijing InnoCare Pharma completes enrolment in phase-II trial for Plaque psoriasis in China (PO) (NCT06109818)
- 28 Mar 2024 Efficacy, safety and pharmacokinetics data from a phase I trial in Psoriasis released by InnoCare
- 28 Mar 2024 InnoCare completes the phase I trial in Psoriasis in China (NCT05451199)